What anabolic steroids actually are — and why they aren’t testosterone therapy.
There’s a lot of confusion between testosterone therapy and anabolic-androgenic steroid (AAS) use, both in the lay public and the medical community. Some of that confusion is structural: the AAS molecules and the testosterone molecule are both built on the same four-ring steroid scaffold, and that scaffold is derived from cholesterol. They look related on paper. Clinically, they behave very differently.
When steroid chemistry was first developed between the 1940s and the 1960s, the research goal was to create a steroid molecule with mostly muscle-building (anabolic) activity and very little secondary-sex-characteristic (androgenic) activity — so it could be used in children, women, or older adults without causing acne, body-hair changes, or vocal deepening. That clean separation was never achieved, but the work produced hundreds of steroid compounds with more muscle-building effect than testosterone itself. Modifications at the A, B, and C rings of testosterone and at the 17 and 19-carbon positions made the resulting molecules 3–30 times more anabolic than testosterone (Kicman, 2008 — Pharmacology of Anabolic Steroids, British Journal of Pharmacology; Kuhn, 2002 — Anabolic Steroids, Recent Progress in Hormone Research). That increased anabolic potency is exactly what makes them the preferred illicit compound in competitive sports and bodybuilding — and exactly what makes their side-effect profile look nothing like physiologic testosterone’s.
Why the doses matter more than the molecule
The compound being 3–30 times more potent than testosterone is only half the picture. The other half is that recreational AAS use involves supraphysiologic doses — doses that push testosterone-equivalent levels 10–100 times above the normal range. Users typically stack four to eight different steroids together and inject several times per week (sometimes per day). Cycles last 8–16 weeks. Pyramid cycles start low, ramp high, then taper. Either way, peak hormone levels are far above anything the human endocrine system was built to handle, and the side effects follow from that excess — not from the steroid molecule alone.
The supraphysiologic doses commonly used recreationally exceed what the liver is built to clear, which is why cycles are run on/off rather than continuously. If the compounds were taken at those doses without breaks, the cumulative damage to multiple organ systems would compound quickly. The cycling pattern is itself an admission that the compounds are dose-toxic at the levels being used.
Where these compounds sit in U.S. medicine
From a prescribing standpoint, anabolic-androgenic steroids are restricted to specific FDA-approved indications: HIV-associated muscle wasting, severe burn-injury recovery, certain forms of delayed puberty in adolescent males, and a small set of other narrow clinical contexts. Outside those indications, AAS are Schedule III controlled substances under U.S. federal law, and physicians don’t prescribe them for muscle-building or athletic-performance purposes. That regulatory posture is part of why honest medical care for men who use AAS is hard to find: most clinics that operate in the space either prescribe AAS off-label (which carries real risk for the prescriber) or refuse to engage with AAS-using patients at all. Neither serves the patient.
